Clinical Trials Arena on MSN15d
PepGen reports positive initial data from Phase I DM1 therapy trialPepGen has shared positive initial data from its ongoing FREEDOM-DM1 Phase I trial, which is evaluating PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1). In the 5mg/kg and 10mg/kg dose ...
Dose-dependent increase in muscle tissue concentrations of PGN-EDODM1 was observed at 5 mg/kg (n=6) and at 10 mg/kg (n=5) 1 at day 28. While single-dose studies have not demonstrated improved ...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...
After PepGen (PEPG) announced initial clinical data from the five and ten mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial ...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transfo ...
“This decision enables us to focus resources on completing CONNECT1, as well as rapidly advancing our FREEDOM studies in myotonic dystrophy type 1 with PGN-EDODM1, in which we recently reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback